X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ASTRAZENECA PHARMA with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs ABBOTT INDIA - Comparison Results

ASTRAZENECA PHARMA    Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA ABBOTT INDIA ASTRAZENECA PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 115.8 35.1 330.2% View Chart
P/BV x 16.5 10.1 162.6% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ASTRAZENECA PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-14
ABBOTT INDIA
Mar-17
ASTRAZENECA PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs1,2855,190 24.8%   
Low Rs6344,351 14.6%   
Sales per share (Unadj.) Rs189.61,382.9 13.7%  
Earnings per share (Unadj.) Rs-0.2130.2 -0.2%  
Cash flow per share (Unadj.) Rs3.8137.9 2.8%  
Dividends per share (Unadj.) Rs040.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs68.6652.7 10.5%  
Shares outstanding (eoy) m25.0021.25 117.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.13.4 146.7%   
Avg P/E ratio x-4,712.736.6 -12,861.0%  
P/CF ratio (eoy) x249.634.6 721.6%  
Price / Book Value ratio x14.07.3 191.3%  
Dividend payout %030.7 0.0%   
Avg Mkt Cap Rs m23,988101,373 23.7%   
No. of employees `0001.63.1 50.6%   
Total wages/salary Rs m1,6053,453 46.5%   
Avg. sales/employee Rs Th3,040.29,531.9 31.9%   
Avg. wages/employee Rs Th1,029.21,119.9 91.9%   
Avg. net profit/employee Rs Th-3.3897.3 -0.4%   
INCOME DATA
Net Sales Rs m4,74029,387 16.1%  
Other income Rs m92576 16.0%   
Total revenues Rs m4,83229,963 16.1%   
Gross profit Rs m-1303,973 -3.3%  
Depreciation Rs m101164 61.6%   
Interest Rs m020 0.0%   
Profit before tax Rs m-1394,365 -3.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1390-   
Tax Rs m51,598 0.3%   
Profit after tax Rs m-52,767 -0.2%  
Gross profit margin %-2.713.5 -20.3%  
Effective tax rate %-3.736.6 -10.0%   
Net profit margin %-0.19.4 -1.1%  
BALANCE SHEET DATA
Current assets Rs m2,72618,906 14.4%   
Current liabilities Rs m2,4356,297 38.7%   
Net working cap to sales %6.142.9 14.3%  
Current ratio x1.13.0 37.3%  
Inventory Days Days7462 118.6%  
Debtors Days Days4122 188.4%  
Net fixed assets Rs m1,0351,159 89.3%   
Share capital Rs m50213 23.5%   
"Free" reserves Rs m94213,657 6.9%   
Net worth Rs m1,71613,869 12.4%   
Long term debt Rs m00-   
Total assets Rs m4,15620,638 20.1%  
Interest coverage xNM215.0-  
Debt to equity ratio x00-  
Sales to assets ratio x1.11.4 80.1%   
Return on assets %-0.113.5 -0.9%  
Return on equity %-0.319.9 -1.5%  
Return on capital %031.6 0.0%  
Exports to sales %5.70-   
Imports to sales %6.50-   
Exports (fob) Rs m270NA-   
Imports (cif) Rs m306NA-   
Fx inflow Rs m3750-   
Fx outflow Rs m4700-   
Net fx Rs m-960-   
CASH FLOW
From Operations Rs m-83,072 -0.3%  
From Investments Rs m-146-1,554 9.4%  
From Financial Activity Rs m862-898 -96.1%  
Net Cashflow Rs m709621 114.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 75.0 100.0%  
Indian inst/Mut Fund % 0.3 7.9 3.8%  
FIIs % 15.7 0.1 15,700.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 17.1 53.2%  
Shareholders   12,856 18,270 70.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   NOVARTIS  JUBILANT LIFE SCIENCES  BIOCON LTD  STERLING BIOTECH  NATCO PHARMA  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade on a Negative Note; Sensex Down Over 160 Points(12:30 pm)

After opening the day marginally higher, share markets in India witnessed selling pressure and are presently trading on a negative note.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Looking Beyond the Colourful Prism of This Airline Company(Sector Info)

May 10, 2018

Can Interglobe Aviation Safely Fly Out of Turbulence?

HDFC Prudence Fund Now HDFC Balanced Advantage Fund - Time To Sell?(Outside View)

May 9, 2018

PersonalFN provides detail analysis on HDFC Balanced Advantage Fund (erstwhile HDFC Prudence Fund and HDFC Growth Fund).

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


May 21, 2018 02:23 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS